ArriVent BioPharma’s (AVBP) Outperform Rating Reaffirmed at Oppenheimer

ArriVent BioPharma (NASDAQ:AVBP)‘s stock had its “outperform” rating reissued by investment analysts at Oppenheimer in a report released on Friday,Benzinga reports. They currently have a $50.00 target price on the stock, up from their prior target price of $44.00. Oppenheimer’s target price would suggest a potential upside of 105.17% from the stock’s previous close.

A number of other research firms have also issued reports on AVBP. Citigroup boosted their target price on ArriVent BioPharma from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, January 21st. Zacks Research upgraded shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, December 5th. BTIG Research started coverage on shares of ArriVent BioPharma in a report on Wednesday, December 10th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, HC Wainwright boosted their price target on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $41.11.

ArriVent BioPharma Trading Down 3.5%

Shares of AVBP traded down $0.88 during mid-day trading on Friday, hitting $24.37. 781,627 shares of the company’s stock were exchanged, compared to its average volume of 467,482. ArriVent BioPharma has a fifty-two week low of $15.47 and a fifty-two week high of $27.22. The business’s 50 day moving average is $22.17 and its two-hundred day moving average is $20.89. The firm has a market capitalization of $1.01 billion, a P/E ratio of -5.75 and a beta of 0.99.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, equities research analysts forecast that ArriVent BioPharma will post -2.74 earnings per share for the current year.

Hedge Funds Weigh In On ArriVent BioPharma

A number of large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in ArriVent BioPharma by 27.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock valued at $40,000 after buying an additional 438 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of ArriVent BioPharma by 0.7% in the fourth quarter. Wellington Management Group LLP now owns 82,278 shares of the company’s stock valued at $1,655,000 after acquiring an additional 532 shares in the last quarter. Woodline Partners LP boosted its stake in shares of ArriVent BioPharma by 0.4% during the first quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock valued at $2,706,000 after acquiring an additional 576 shares during the last quarter. Dimensional Fund Advisors LP increased its position in ArriVent BioPharma by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 14,743 shares of the company’s stock worth $297,000 after purchasing an additional 585 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock worth $56,000 after purchasing an additional 609 shares in the last quarter. Hedge funds and other institutional investors own 9.48% of the company’s stock.

More ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Unusually large call buying: Traders bought ~1,832 call options on Friday (?321% above typical call volume). Heavy call activity can indicate speculative bullish bets or hedging by sophisticated traders, which may drive short?term upside interest in the shares.
• Positive Sentiment: HC Wainwright raised its price target from $42 to $44 and maintained a “buy” rating — implying ~83% upside from the cited $24.05 reference price. Analyst optimism and a higher target can attract momentum and institutional interest. Benzinga
• Positive Sentiment: Quarterly EPS beat: AVBP reported (?$0.78) EPS vs. consensus (?$0.87), beating by $0.09. An earnings beat for a clinical?stage biotech reduces short?term execution risk and can support valuation re?rating. Earnings Release
• Positive Sentiment: Broker consensus: Coverage summary lists a “Moderate Buy” consensus from brokerages, which reinforces the positive analyst narrative and can support longer?term inflows. Brokerage Consensus
• Neutral Sentiment: Full?year 2025 financial results and company update were published (press release). The release provides corporate outlook and financials that investors will parse for cash runway, R&D progress and guidance — important but not an immediate directional catalyst until details are digested. Full Year 2025 Results
• Neutral Sentiment: Short?interest data reported as zero shares with NaN changes — likely a data anomaly or reporting quirk. This makes short?interest an unreliable driver currently; absence of meaningful short positions would remove a potential squeeze dynamic.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.